Table 4.
Comparison of Clinical Characteristics Between the Good and Poor Adherence Groups
| Dupilumab Adherence | p-value | ||
|---|---|---|---|
| Good (n = 200) | Poor (n = 83) | ||
| Sex ratio, female: male, n | 69:131 | 37:46 | 0.1380 |
| Age, years (median [IQR]) | 47.0 (37.0–57.0) | 43.0 (35.0–49.5) | 0.0047 |
| Duration of dupilumab use, days (median [IQR]) | 319.5 (198.0–610.5) | 585.0 (487.5) | <0.0001 |
| Pain, VAS score (median [IQR]) | 5.0 (1.8–7.1) | 5.0 (2.5–4.0) | 0.5284 |
| Syringe, n (%) | 54 (27.0) | 34 (41.0) | 0.0267 |
| Syringe with an aid device, n (%) | 13 (6.5) | 8 (9.6) | |
| Pen, n (%) | 133 (66.5) | 41 (49.4) | |
| AD, n (%) | 82 (41.0) | 56 (67.5) | 0.0002 |
| BA, n (%) | 43 (21.5) | 13 (15.7) | |
| CRSwNPs, n (%) | 75 (37.5) | 14 (16.9) | |
Note: All values are described as median (interquartile range).
Abbreviations: AD, atopic dermatitis; BA, bronchial asthma; CRSwNPs, chronic rhinosinusitis with nasal polyps; IQR, interquartile range; VAS, visual analog scale.